Dispositionof patients in the acuteVTE treatment study and secondary VTE prevention study by thrombophilia status. In the acute VTE treatment study, 267 patients were randomized and all but 1 patient randomized to dabigatran were treated; 176 patients received dabigatran and 90 received SOC. In the secondary VTE prevention study, 213 of 221 enrolled patients received dabigatran.